{'fraction_non_alphanumeric': 0.0273224043715847, 'fraction_numerical': 0.008743169398907104, 'mean_word_length': 5.735294117647059, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
GH/IGF‐1 axis in patients with subclinical hypothyroidism

Introduction Changes in thyroid status have a major effect on the GH/IGF-1 axis. Subclinical hypothyroidism occurs in 4%–10% of the general population, and is especially prevalent in elderly women. The natural history of subclinical hypothyroidism is variable; thyroid function normalizes spontaneously in some subjects, whereas it progresses to overt hypothyroidism in others. Potential risks of subclinical hypothyroidism include progression to overt hypothyroidism, dyslipidaemia, cardiovascular complications, and neurological and neuropsychiatric effects. To the best of our knowledge, there are no data about the possible influences of subclinical hypothyroidism on the GH/IGF-1 axis. Our aim was to evaluate serum concentrations of GH, IGF-1 and IGFBP-3 in patients with subclinical hypothyroidism before and after normalization of thyroid function.